We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
AN2 Therapeutics Inc | NASDAQ:ANTX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.04 | -1.54% | 2.55 | 2.39 | 2.62 | 2.64 | 2.54 | 2.61 | 91,221 | 01:00:00 |
Oral presentation pertaining to epetraborole:
Symposium: New Antimicrobials and ID Diagnostics in the Pipeline #1Title: Epetraborole: A Novel, Oral Antibiotic for NTM Lung DiseaseDate: Thursday, October 20, 2022 from 8:00-9:00am ETPresenter: Paul Eckburg, M.D.
Poster presentations pertaining to epetraborole:
Title: Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 StudiesDate: Thursday, October 20, 2022 from 12:15-1:30pm ETPoster Session: A2. PK/PD StudiesPoster Number: 593
Title: Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung DiseaseDate: Thursday October 20, 2022 from 12:15-1:30pm ETPoster Session: A2. PK/PD studies Poster Number: 619
Title: Dose-response Studies of the Novel Bacterial Leucyl-tRNA Synthetase Inhibitor, Epetraborole, in the Intracellular Hollow Fiber System Model of Mycobacterium avium Complex Lung DiseaseDate: Saturday, October 22, 2022 from 12:15-1:30pm ETPoster Session: A1. Antimicrobial Novel AgentsPoster Number: 1697
Title: Pharmacokinetics/pharmacodynamics of Epetraborole, a Novel Bacterial Leucyl-tRNA Synthetase Inhibitor, and High Intracellular Penetration in the Intracellular Hollow Fiber System Model of Mycobacterium avium Complex Lung DiseaseDate: Saturday, October 22, 2022 from 12:15-1:30pm ETPoster Session: A1. Antimicrobial Novel AgentsPoster Number: 1698
Title: Epetraborole, a Novel Bacterial Leucyl-tRNA Synthetase Inhibitor, Demonstrates Potent Efficacy and Improves Efficacy of Standard of Care Regimen Against Mycobacterium avium complex in a Chronic Mouse Lung Infection ModelDate: Saturday, October 22, 2022 from 12:15-1:30pm ETPoster Session: A1. Antimicrobial Novel AgentsPoster Number: 1704
Title: In Vitro Activities of Epetraborole, a Novel Bacterial Leucyl-tRNA Synthetase Inhibitor, in Drug Combinations Against Nontuberculous Mycobacteria Including Resistance Frequency and MIC Characterization of Mycobacterium avium ATCC 700898 Epetraborole-resistant MutantsDate: Saturday, October 22, 2022 from 12:15-1:30pm ETPoster Session: A1. Antimicrobial Novel AgentsPoster Number: 1712
Title: In Vitro Activities of Epetraborole, a Novel Bacterial Leucyl-tRNA Synthetase Inhibitor, Against Mycobacterium avium Complex IsolatesDate: Saturday, October 22, 2022 from 12:15-1:30pm ETPoster Session: A1. Antimicrobial Novel AgentsPoster Number: 1713
Title: In Vitro Drug-Drug Interaction Evaluation of Epetraborole, a Novel Bacterial Leucyl-tRNA Synthetase InhibitorDate: Saturday, October 22, 2022 from 12:15-1:30pm ETPoster Session: A1. Antimicrobial Novel AgentsPoster Number: 1716
Title: Tolerability and Pharmacokinetics of Oral Epetraborole at the Predicted Therapeutic Dosage for Mycobacterium avium Complex (MAC) Lung Disease: A Phase 1b Dose-ranging and Food Effect StudyDate: Saturday, October 22, 2022 from 12:15-1:30pm ETPoster Session: A1. Antimicrobial Novel AgentsPoster Number: 1727
About AN2 Therapeutics, Inc. AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. Our lead candidate is epetraborole, which we are studying in a pivotal Phase 2/3 trial as a once-daily, oral treatment with a novel mechanism of action for patients with NTM lung disease, a rare, chronic, and progressive infectious disease caused by bacteria, known as mycobacteria, that leads to irreversible lung damage and can be fatal. For more information, please visit our website at www.an2therapeutics.com.
COMPANY CONTACT:Lucy O. DayChief Financial Officerl.day@an2therapeutics.com
INVESTOR AND MEDIA CONTACT:Anne Bowdidgeir@an2therapeutics.com
1 Year AN2 Therapeutics Chart |
1 Month AN2 Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions